Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | CES1 | P23141 | 3/20 | 0.61 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050407 | 0.89 | CES1 (0.54) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL21645829 | 0.84 | FAAH (0.64) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL7444620 | 0.84 | FAAH (0.81) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL7371238 | 0.84 | FAAH (0.68) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL21645499 | 0.83 | FAAH (0.83) | FAAHCES1NCEH1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL21645495 | 0.81 | FAAH (0.81) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL7367753 | 0.79 | FAAH (0.60) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL6808997 | 0.78 | CES1 (0.54) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL6206827 | 0.76 | CES1 (0.53) | FAAHCES1NCEH1HDAC3HDAC4 | |
| SCHEMBL13764125 | 0.76 | FAAH (1.00) | FAAHCES1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| CN-101663301-B | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS CH | 2012-06-06 | — | — | CN | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| CN-101663301-A | Imidazopyridine derivatives as the replacement of melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS CH | 2010-03-03 | — | — | CN | disclosed |
| EP-2144907-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | MC4R, MC3R, MC5R | FAAH 1488/4885CES1 4666/4885NCEH1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.